Biotech SF
San Francisco Bay Area biotech stories.
Monday, July 30, 2012
Ultragenyx raises $15 million
Ultragenyx Prsident and CEO Emil Kakkis.
Orphan drug developer Ultragenyx Pharmaceutical Inc. has gathered $15.1 million toward a goal of raising $30.1 million, according to a Securities and Exchange Commission filing Monday.
The Novato company, started by former
BioMarin Pharmaceutical Inc.
Chief Medical Officer
Emil Kakkis
, has
won orphan drug designation for two drugs
from the Food and Drug Administration as well as from
European drug regulators
.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment